Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.A, non-specified, prohibited in competition. The future 2027 List retains this classification. [1] [2]
2026 and 2027 List, S6.A, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context and risks
US oral modafinil labeling covers excessive sleepiness associated with narcolepsy, obstructive sleep apnea or shift-work disorder in adults. Warnings include serious rash, hypersensitivity and psychiatric effects. It is not a substitute for treatment of the underlying obstruction in sleep apnea. [3] [4]
- These patient-label findings do not apply automatically to adrafinil, hydrafinil or fluorinated analogues.
Related isomer
Armodafinil is the R-enantiomer of modafinil according to the reviewed label. This chemical relationship should be recorded explicitly rather than treating all related names as interchangeable product synonyms. [3] [4]
- S6 covers optical isomers; an unprinted isomer name should not trigger an automated sanction calculation.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- M1. DailyMed. Armodafinil labeling, R-enantiomer identity and serious-rash warnings; modafinil labeling. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Armodafinil clinical pharmacology · Indications; sections 5 and 12
- M1. DailyMed. Armodafinil labeling, R-enantiomer identity and serious-rash warnings; modafinil labeling. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Armodafinil clinical pharmacology · Indications; sections 5 and 12
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.